Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vistra Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vistra Corp trades at $148.59 (market cap $54.49B). The key difference: Vistra Corp is far larger — about 11.2× Travere Therapeutics Inc. Common Stock's market cap, and Vistra Corp pays a 0.57% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vistra Corp for 33 Days on average.
| TVTX | VST | |
|---|---|---|
Market Cap | $4.88B | $54.49B |
Volume | 1,668,577 | 5,289,982 |
Sector | Health | Utilities |
52-Week High | $67.52 | $210.85 |
52-Week Low | $26.79 | $134.71 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.01B | $76.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Vistra Corp (VST) trades at $162.36, up 2.68% with strong institutional support and bullish technical indicators. The stock shows impressive profitability with 75.73% ROE and 11.55% net margin, though recent earnings were mixed with Q1 beat but Q2 miss. Recent developments include a $4.2 billion government loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra presents significant upside potential with a $215.23 consensus price target (32.5% upside) and 91.3% buy ratings. The company benefits from nuclear power expansion and AI infrastructure demand, though risks include execution of growth initiatives and energy market volatility. Current valuation at 27.38 P/E appears reasonable given growth prospects in the power generation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
